Ocumetics Technology Announces Amendment to Brokered LIFE Offering Led by Centurion One Capital

Executive Summary

• Ocumetics Technology Corp. amended its previously announced broker‑driven private placement, increasing the offering size to up to 4,166,666 units at $0.60 per unit for gross proceeds of up to $2,500,000.
• The amendment adds an option for the lead agent, Centurion One Capital Corp., to sell an additional 625,000 units at the same price, potentially raising another $375,000.
• Proceeds are earmarked primarily for the company’s first‑in‑human clinical trials, ongoing R&D, and general corporate purposes, representing a material financing boost for its ophthalmic technology program.

Key Details

• Amended Issue Price: $0.60 per unit (each unit = 1 common share + 1 warrant).
• Units Offered: Up to 4,166,666 units → gross proceeds up to $2.5 M.
• Warrant Terms: Each warrant allows purchase of one common share at an exercise price of $0.75 for three years from closing.
• Lead Agent Option: Up to 625,000 additional units at the same $0.60 price → potential extra proceeds of $375,000; exercisable up to two business days before the Closing Date.
• Closing Timeline: Expected on or around December 29, 2025, subject to customary conditions and TSX Venture Exchange approval.
• Use of Proceeds: Funding first‑in‑human clinical trials, continued research & development of intraocular lens technology, and general corporate purposes (material positive impact on cash resources).
• Regulatory Exemptions: Offered under Canadian listed issuer financing exemption (NI 45‑106) and U.S. securities law exemptions; no statutory hold period in Canada.
• Related Party Participation: Insiders and affiliates may participate; expected to be exempt from formal valuation/minority shareholder approval under MI 61‑101 because the transaction does not exceed 25% of market cap.

Notable Quotes

• “The amended financing will provide essential capital to advance our groundbreaking intraocular lens program into first‑in‑human trials, accelerating our mission to transform vision correction,” – Dean Burns, President and CEO.